Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Celltrion And Pfizer Cement Victory On Infliximab

Janssen's Cell-Culture Media Patent Not Infringed By Inflectra/Remsima

Executive Summary

Celltrion and Pfizer are now two for two in their legal battles with Janssen over US patents shielding the originator's Remicade (infliximab), with a US Court of Appeals once again siding with the biosimilars developers.

You may also be interested in...



Pfizer And J&J Settle Remicade Antitrust Litigation

Pfizer and Johnson & Johnson have settled long-running US antitrust litigation over claims that contracts and deals for the Remicade brand were set up to dampen competition from infliximab biosimilars.

Pfizer and Celltrion win cell-culture spat

Pfizer’s Hospira and its biosimilar development partner Celltrion have won a summary judgement from a Massachusetts district court affirming that the cell-culture media they use to produce the Inflectra/Remsima (infliximab-dyyb) biosimilar does not infringe Janssen’s US patent 7,598,083 under the doctrine of equivalents.

American Regent’s Vasopressin Questioned As Eagle Prepares ANDA Launch

With Eagle set to launch its long-awaited vasopressin ANDA product on 17 January, the US firm’s management told investors it was unsure what its launch meant for the 505(b)(2) rival product in the hands of American Regent.

Topics

Related Companies

UsernamePublicRestriction

Register

GB149687

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel